New Enhancing CLIA Act: What Lab Directors Need to Know
The proposal seeks to move any future LDT authority away from the FDA
Already a member? Log in here
Essential
Subscribe today for access to
Articles and Reports
How to Stay Ahead of Anticipated CLIA Deficiencies
Consultant Nora Hess offers suggestions for clinical labs to navigate these problems
Already a member? Log in here
FDA Watch: Natera, Valar Labs Receive FDA Clearances for Bladder Cancer Tests
Natera’s assay focuses on the need for adjuvant therapy, while Valar’s test stratifies risk of recurrence
Already a member? Log in here
News-At-A-Glance: Louisiana Supreme Court Reverses $330 Million Judgment
...
Already a member? Log in here
News-At-A-Glance: Lawsuit Challenging OIG Special Fraud Alert Dismissed
...
Already a member? Log in here
G2 Compliance Corner
...
Already a member? Log in here
More Trouble in the Toxicology Laboratory Marketplace
...
Already a member? Log in here
Incorporating the 2014 OIG Work Plan Into Your Annual Review Processes
...
Already a member? Log in here
Upcoming Conferences
...
Already a member? Log in here